Patents by Inventor Gideon Dreyfuss

Gideon Dreyfuss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10738345
    Abstract: This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 11, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Publication number: 20190071710
    Abstract: This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.
    Type: Application
    Filed: March 26, 2018
    Publication date: March 7, 2019
    Applicant: The Tructees Of The University Of Pennsylvania
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Patent number: 9926588
    Abstract: This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: March 27, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Patent number: 9650684
    Abstract: The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes in the signals that regulate splicing dependent processes such as those that modulate the EJC, splicing-dependent export, localization or translation efficiency. The present invention further uses the cell-based screen to identify several small molecules that modulate both constitutive and alternative splicing. Accordingly, the present invention includes general or alternative splicing inhibitors identified using the assay described herein. The present invention also provides methods of treating a subject having a condition associated with aberrant target RNA expression.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: May 16, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Ihab Younis, Lili Wan
  • Publication number: 20150191724
    Abstract: The present invention relates to the discovery of a novel global gene expression regulation mechanism whereby U1 snRNP (U1) protects pre-mRNAs. In one embodiment, the invention includes compositions and methods for regulating gene expression and treating diseases associated with dysregulated gene expression.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 9, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Jung Min Oh, Anna Maria Pinto, Ihab Younis, Michael George Berg, Daisuke Kaida
  • Patent number: 9040491
    Abstract: The present invention includes methods for modulating the expression of a gene or mRNA in a cell using small nuclear RNAs comprising specific sequence and structural features and further comprising a nucleic acid cargo.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: May 26, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Jeongsik Yong, Tracey (Golembe) Polsky
  • Patent number: 8993741
    Abstract: The present invention includes an isolated nucleic acid comprising a nucleic acid sequence encoding a SMN?7 degron and the encoded polypeptide. The invention also includes inhibitors of SMN?7 degron. The invention also includes compositions and methods for mitigating SMN deficiency by targeting inhibition of factors that mediate SMN?7-degron dependent degradation of SMN?7.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: March 31, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Sungchan Cho
  • Patent number: 8822168
    Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 2, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
  • Patent number: 8802380
    Abstract: This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: August 12, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Publication number: 20120322852
    Abstract: The present invention includes an isolated nucleic acid comprising a nucleic acid sequence encoding a SMN?7 degron and the encoded polypeptide. The invention also includes inhibitors of SMN?7 degron. The invention also includes compositions and methods for mitigating SMN deficiency by targeting inhibition of factors that mediate SMN?7-degron dependent degradation of SMN?7.
    Type: Application
    Filed: November 17, 2010
    Publication date: December 20, 2012
    Inventors: Gideon Dreyfuss, Sungchan Cho
  • Publication number: 20120322079
    Abstract: This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.
    Type: Application
    Filed: June 27, 2012
    Publication date: December 20, 2012
    Inventors: Gideon DREYFUSS, Mumtaz Kasim
  • Patent number: 8227203
    Abstract: This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: July 24, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Publication number: 20120157474
    Abstract: The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes in the signals that regulate splicing dependent processes such as those that modulate the EJC, splicing-dependent export, localization or translation efficiency. The present invention further uses the cell-based screen to identify several small molecules that modulate both constitutive and alternative splicing. Accordingly, the present invention includes general or alternative splicing inhibitors identified using the assay described herein. The present invention also provides methods of treating a subject having a condition associated with aberrant target RNA expression.
    Type: Application
    Filed: May 21, 2010
    Publication date: June 21, 2012
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Gideon Dreyfuss, Ihab Younis, Lili Wan
  • Patent number: 8188070
    Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: May 29, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Jin Wang
  • Publication number: 20100297665
    Abstract: This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.
    Type: Application
    Filed: June 4, 2008
    Publication date: November 25, 2010
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Publication number: 20100273179
    Abstract: This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.
    Type: Application
    Filed: June 4, 2008
    Publication date: October 28, 2010
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Publication number: 20100234402
    Abstract: This invention provides methods of treating and abrogating spinal muscular atrophy by administering an antioxidant. Additionally, the invention provides a method of protecting the SMN protein by administering an antioxidant.
    Type: Application
    Filed: June 2, 2008
    Publication date: September 16, 2010
    Inventors: Gideon Dreyfuss, Lili Wan
  • Publication number: 20100197661
    Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.
    Type: Application
    Filed: March 23, 2010
    Publication date: August 5, 2010
    Inventors: Gideon Dreyfuss, Jin Wang
  • Patent number: 7691847
    Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: April 6, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Jin Wang
  • Publication number: 20090156789
    Abstract: The invention relates to an isolated nucleic acid encoding a eukaryotic Survival of Motor Neuron-Interacting Protein 1 (SIP1), compositions comprising SIP1 and SIP1 and the spinal muscular atrophy (SMA) disease gene product Survival of Motor Neuron protein (SMN), and diagnostic and therapeutic assays directed to SMA. The invention also relates to another protein that specifically interacts with SMN and is a component of gems, designated Gemin3, and the nucleic acid encoding the protein. Additionally, the invention relates to a novel cell line wherein the endogenous SMN genes have been deleted and where an exogenous nucleic acid encoding SMN has been inserted into the cell such that expression of SMN in the cell is under the control of an inducible promoter. This novel cell line provides a stable genetic system for the study of SMA and for the development of SMA therapeutics.
    Type: Application
    Filed: October 27, 2008
    Publication date: June 18, 2009
    Inventors: Gideon Dreyfuss, Utz Fischer, Qing Liu, Bernard Charroux, Livio Pellizzoni